MYGN

NASDAQ 已收盘

Myriad Genetics

3.88 USD
+0.09+2.37%
盘后 3.18 0.00%
2026-09-15
市值
$369.21M
市盈率
EPS
-1.20
股息率
52 周区间
2.74 – 8.59
成交量
4.68M
Beta
1.68
目标价
3.37
52W 低 2.7452W 高 8.59
价格走势

公司简介

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion...